Please assess the completion status of the following clinical trial:

Trial Title: Crystalline Glucosamine Sulfate Therapy in Hand Osteoarthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Mono or bilateral primary HOA and concomitant knee OA, according to the American College of Rheumatology (ACR) criteria~* Treatment for at least 6 consecutive months with crystalline GS at the daily dose of 1500 mg in addition to the conventional therapy or with usual care alone.~* HOA symptoms duration for at least 3 months defined as global hand pain score superior to 40 mm on a 0-100 VAS and a FIHOA score of at least 6.~* Radiographic evidence of HOA within the previous 6 months with a radiological score of II-III (using the Kellgren method).~Exclusion Criteria:~* Erosive Osteoarthritis of the hand~* Medical history of any inflammatory joint disease, septic arthritis, previous articular fracture of the concerned joints, monarticular post-traumatic OA of the finger, a history or the presence of any other rheumatic diseases that could cause secondary OA, such as hemochromatosis.~* Ongoing therapy with opioid analgesics and any kind of topical treatment~* Therapy with SYSADOAs other than GS, steroids by any route of administration and intra-articular injection of any joint with hyaluronic acid during the previous 6 months.~* Contraindications or special warnings for GS presented in the data sheet.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Glucosamine Sulfate Group (GS Group) (Type: None): GS Group is treated for at least 6 consecutive months with a single daily dose of 1500 mg of crystalline GS (powder sachets), in addition to conventional therapy.
- Control Group (Type: None): Control Group receive only usual care therapy. The conventional therapy includes exercise for HOA and treatment with acetaminophen or oral NSAIDs or COX-2 inhibitors (150 mg Diclofenac tablets, 20 mg Piroxicam tablets, 550 mg Naproxen tablets, 200 mg Aceclofenac, 600 mg Ibuprofen tablets, 200 mg Celecoxib tablets, 60 mg Etoricoxib tablets).

Based on this trial design, predict the completion outcome and termination type (if applicable).